SBC Medical Group Holdings Surpasses Q4 2025 Expectations with Robust Growth in Customer Spending and Unit Economics
SBC Medical Group Holdings, a leading provider of medical services, has delivered a strong performance in the fourth quarter of fiscal 2025. CEO Yoshiyuki Aikawa highlighted key highlights from the company's clinic operations during the recent conference call, showcasing a significant rebound in average revenue per customer and genuine momentum in underlying trends.
As of December 2025, SBC Medical Group Holdings operated 283 locations and served $6.63 million customers over the trailing 12 months. Total clinic revenue for the full year reached $1,163 million, representing a 2% year-over-year growth. Notably, average revenue per customer rebounded significantly in Q4, reaching $316 - an 11% increase from the prior year.
CEO Aikawa expressed optimism about the trend, stating that SBC Medical Group Holdings is now seeing both customer growth and improving unit economics moving in the same direction. This development has been reflected in charts showing average revenue per visit recovering steadily on a quarterly basis, with total clinic revenue following an upward trajectory.
The company's domestic core operations also made significant progress during FY 2025. Recovery in customer spending, expansion of dermatology and AGA hair loss treatment networks, further expansion in orthopedics and fertility treatment, as well as the opening of NEO Skin Clinic and Hadano Aozora Clinic, strengthening its domestic platform through a series of additions.
Internationally, SBC Medical Group Holdings made concrete progress by making a strategic investment in OrangeTwist in the United States and forming a partnership with BLEZ ASIA in Thailand. These developments mark the company's first tangible steps toward a broader global presence.
Financially, full year revenue came in at $174 million - a 15% decrease from the prior year. However, net income attributable to shareholders grew 9% year-over-year to $51 million, with EPS increasing 4% to $0.50. The key driver behind this improvement was the absence of significant one-time costs associated with the listing process and asset revaluations.
CEO Aikawa highlighted that while revenue reflected the impact of business restructuring initiatives, the company's cost structure has normalized, and profitability metrics have improved - a defining story of fiscal year 2025. EBITDA was $70 million with an EBITDA margin of 40.4%, maintaining a strong level of profitability.
The company's core strategic pillars remain unchanged: aesthetic dermatology, non-aesthetic healthcare, and global expansion. However, SBC Medical Group Holdings is introducing two unifying themes across these pillars - longevity and AI-driven healthcare. The goal is to build a healthcare platform that supports people in living longer, healthier, and more vibrant lives.
